Tomoya Ohno

Summary

Affiliation: Ono Pharmaceutical Co
Country: Japan

Publications

  1. ncbi request reprint Absorption enhancing effect of labrasol on the intestinal absorption of insulin in rats
    Sudarat Eaimtrakarn
    Department of Pharmacokinetics, Kyoto Pharmaceutical University, Japan
    J Drug Target 10:255-60. 2002
  2. doi request reprint Effect of itraconazole on the pharmacokinetics of imidafenacin in healthy subjects
    Tomoya Ohno
    Pharmacokinetic Research Laboratories, Ono Pharmaceutical Co Ltd, 17 2 Wadai Tsukuba, Ibaraki, Japan
    J Clin Pharmacol 48:330-4. 2008
  3. pmc Absolute bioavailability of imidafenacin after oral administration to healthy subjects
    Tomoya Ohno
    Pharmacokinetic Research Laboratories, Ono Pharmaceutical Co, Ltd, Ibaraki, Japan
    Br J Clin Pharmacol 65:197-202. 2008
  4. doi request reprint The prediction of human response to ONO-4641, a sphingosine 1-phosphate receptor modulator, from preclinical data based on pharmacokinetic-pharmacodynamic modeling
    Tomoya Ohno
    Pharmacokinetic Research Laboratories, Ono Pharmaceutical Co, Ltd, Ibaraki, Japan
    Biopharm Drug Dispos 31:396-406. 2010
  5. ncbi request reprint Population pharmacokinetic analysis of a novel muscarinic receptor antagonist, imidafenacin, in healthy volunteers and overactive bladder patients
    Tomoya Ohno
    Pharmacokinetic Research Laboratories, Ono Pharmaceutical Co, Ltd, Ibaraki, Japan
    Drug Metab Pharmacokinet 23:456-63. 2008
  6. doi request reprint Population pharmacokinetics of aprepitant and dexamethasone in the prevention of chemotherapy-induced nausea and vomiting
    Susumu Nakade
    Pharmacokinetic Research Laboratories, Ono Pharmaceutical Co, Ltd, Tsukuba, Ibaraki, Japan
    Cancer Chemother Pharmacol 63:75-83. 2008
  7. ncbi request reprint No effect of imidafenacin, a novel antimuscarinic drug, on digoxin pharmacokinetics in healthy subjects
    Susumu Nakade
    Pharmacokinetic Research Laboratories, Ono Pharmaceutical Co, Ltd, Ibaraki, Japan
    Drug Metab Pharmacokinet 23:95-100. 2008
  8. ncbi request reprint Effect of clarithromycin on the pharmacokinetics of pranlukast in healthy volunteers
    Susumu Nakade
    Pharmacokinetic Research Laboratories, Ono Pharmaceutical Co, Ltd, Ibaraki, Japan
    Drug Metab Pharmacokinet 23:428-33. 2008
  9. ncbi request reprint Population pharmacokinetics and exposure-response relationship of a muscarinic receptor antagonist, imidafenacin
    Chihiro Hasegawa
    Pharmacokinetic Research Laboratories, Ono Pharmaceutical Co, Ltd, Tsukuba, Japan
    Drug Metab Pharmacokinet 28:203-12. 2013
  10. ncbi request reprint Population pharmacokinetics of landiolol hydrochloride in healthy subjects
    Naoki Honda
    Pharmacokinetic Research Laboratories, Ono Pharmaceutical Co, Ltd, Ibaraki, Japan
    Drug Metab Pharmacokinet 23:447-55. 2008

Collaborators

Detail Information

Publications12

  1. ncbi request reprint Absorption enhancing effect of labrasol on the intestinal absorption of insulin in rats
    Sudarat Eaimtrakarn
    Department of Pharmacokinetics, Kyoto Pharmaceutical University, Japan
    J Drug Target 10:255-60. 2002
    ..0 to 1.0 IU/kg. These results suggest the absorption enhancing effect of Labrasol on the intestinal absorption of insulin in rats...
  2. doi request reprint Effect of itraconazole on the pharmacokinetics of imidafenacin in healthy subjects
    Tomoya Ohno
    Pharmacokinetic Research Laboratories, Ono Pharmaceutical Co Ltd, 17 2 Wadai Tsukuba, Ibaraki, Japan
    J Clin Pharmacol 48:330-4. 2008
    ..47-2.16). In conclusion, itraconazole increases the plasma concentrations of imidafenacin by inhibiting CYP3A4. Therefore, itraconazole or potent CYP3A4 inhibitors should be carefully added to imidafenacin drug regimens...
  3. pmc Absolute bioavailability of imidafenacin after oral administration to healthy subjects
    Tomoya Ohno
    Pharmacokinetic Research Laboratories, Ono Pharmaceutical Co, Ltd, Ibaraki, Japan
    Br J Clin Pharmacol 65:197-202. 2008
    ..8%. The pharmacokinetic profiles of imidafenacin after intravenous administration are revealed. The formation of metabolites in the plasma is caused mainly by first-pass effects...
  4. doi request reprint The prediction of human response to ONO-4641, a sphingosine 1-phosphate receptor modulator, from preclinical data based on pharmacokinetic-pharmacodynamic modeling
    Tomoya Ohno
    Pharmacokinetic Research Laboratories, Ono Pharmaceutical Co, Ltd, Ibaraki, Japan
    Biopharm Drug Dispos 31:396-406. 2010
    ..In conclusion, the simulation of human lymphocyte counts based on preclinical data led to the acquisition of useful information for designing future clinical studies...
  5. ncbi request reprint Population pharmacokinetic analysis of a novel muscarinic receptor antagonist, imidafenacin, in healthy volunteers and overactive bladder patients
    Tomoya Ohno
    Pharmacokinetic Research Laboratories, Ono Pharmaceutical Co, Ltd, Ibaraki, Japan
    Drug Metab Pharmacokinet 23:456-63. 2008
    ..In conclusion, we developed a population pharmacokinetic model for imidafenacin that well-described plasma concentration profiles. We also identified the factors affecting imidafenacin pharmacokinetics...
  6. doi request reprint Population pharmacokinetics of aprepitant and dexamethasone in the prevention of chemotherapy-induced nausea and vomiting
    Susumu Nakade
    Pharmacokinetic Research Laboratories, Ono Pharmaceutical Co, Ltd, Tsukuba, Ibaraki, Japan
    Cancer Chemother Pharmacol 63:75-83. 2008
    ....
  7. ncbi request reprint No effect of imidafenacin, a novel antimuscarinic drug, on digoxin pharmacokinetics in healthy subjects
    Susumu Nakade
    Pharmacokinetic Research Laboratories, Ono Pharmaceutical Co, Ltd, Ibaraki, Japan
    Drug Metab Pharmacokinet 23:95-100. 2008
    ..8 to 1.25. The steady-state pharmacokinetics of digoxin is not affected by concomitant administration of imidafenacin in healthy subjects...
  8. ncbi request reprint Effect of clarithromycin on the pharmacokinetics of pranlukast in healthy volunteers
    Susumu Nakade
    Pharmacokinetic Research Laboratories, Ono Pharmaceutical Co, Ltd, Ibaraki, Japan
    Drug Metab Pharmacokinet 23:428-33. 2008
    ..06 (0.91, 1.24) and 1.17 (0.95, 1.45), respectively. In conclusion, clarithromycin and pranlukast could be coadministered without dose adjustment because clarithromycin minimally affected the pharmacokinetics of pranlukast...
  9. ncbi request reprint Population pharmacokinetics and exposure-response relationship of a muscarinic receptor antagonist, imidafenacin
    Chihiro Hasegawa
    Pharmacokinetic Research Laboratories, Ono Pharmaceutical Co, Ltd, Tsukuba, Japan
    Drug Metab Pharmacokinet 28:203-12. 2013
    ..There was no clear relationship between the plasma concentration of imidafenacin and QTc, indicating that concentration-dependent QTc interval prolongation was not observed...
  10. ncbi request reprint Population pharmacokinetics of landiolol hydrochloride in healthy subjects
    Naoki Honda
    Pharmacokinetic Research Laboratories, Ono Pharmaceutical Co, Ltd, Ibaraki, Japan
    Drug Metab Pharmacokinet 23:447-55. 2008
    ..The population pharmacokinetic model for landiolol hydrochloride in healthy subjects was developed and was shown to be appropriate by both bootstrap and leave-one-out cross validation methods...
  11. doi request reprint Population pharmacokinetic and pharmacodynamic modeling of different formulations of ONO-5334, cathepsin K inhibitor, in Caucasian and Japanese postmenopausal females
    Chihiro Hasegawa
    Pharmacokinetic Research Laboratories, Ono Pharmaceutical Co, Ltd, Ibaraki, Japan Department of Clinical Pharmacokinetics, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan
    J Clin Pharmacol 54:23-34. 2014
    ....
  12. ncbi request reprint Population pharmacokinetics of pranlukast hydrate dry syrup in children with allergic rhinitis and bronchial asthma
    Susumu Nakade
    Pharmacokinetic Research Institute, Ono Pharmaceutical Co, Ltd, Wadai Tsukuba, Ibaraki, Japan
    Drug Metab Pharmacokinet 21:133-9. 2006
    ..All the parameters fell within 10% of the bootstrapped mean. In conclusion, the results show that age is the most influential factor for explaining interindividual variability in CL/F, and the difference in diseases does not affect CL/F...